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Abstract
Introduction: Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with
hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy
(NCT) with NET in pre-menopausal breast cancer.
Patients and methods: In this prospective, randomised, phase III study, oestrogen receptor (ER)-positive, HER2-
negative, and lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South
Korea. Enrolled patients were randomly assigned (1:1) to receive 24 weeks of either NCT or NET with goserelin and
tamoxifen. The primary purpose was to evaluate the non-inferiority of NET compared to NCT using clinical
response, assessed by MRI. Besides, pathological complete response rate (pCR), changes in Ki-67 expression, breast
conservation surgery (BCS) rate, and quality of life were included as secondary endpoints.
Results: A total of 187 patients were assigned to receive NCT (n = 95) or NET (n = 92), and 87 patients in each group
completed treatments. More NCT patients had complete response or partial response than NET patients using MRI
(NCT 83.7% vs. NET 52.9%, 95% CI 17.6–44.0, p < 0.001) and callipers (NCT 83.9% vs. NET 71.3%, 95% CI 0.4–24.9, p =
0.046). Three NCT patients (3.4%) and one NET patient (1.2%) showed pCR (p < 0.005). No difference existed in the
conversion rate of BCS (13.8% for NCT vs. 11.5% for NET, p = 0.531) and Ki-67 change (p = 0.114) between the two
groups. Nineteen NCT patients had treatment-related grade 3 or worse events compared with none in the NET group.
Conclusions: Better clinical responses were observed in pre-menopausal patients after 24 weeks of NCT compared to
those observed after NET.
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Background
For hormone-responsive breast cancer, the question of
which patients can safely be spared adjuvant chemother-
apy has been extensively studied. For cases involving
hormone receptor-positive tumours, younger patients (<
35 years old) show a poorer prognosis than older pa-
tients in terms of tamoxifen resistance [1]. However, this
finding does not indicate that young patients should re-
ceive chemotherapy. The greater effects of chemotherapy
on younger patients are likely to be partially explained by the
endocrine effects of chemotherapy on ovarian function. Irre-
spective of the chemotherapy agent administered, iatrogenic
amenorrhea is associated with an increased survival rate in
oestrogen receptive (ER)-positive breast cancer [2, 3], and
amenorrhea is a surrogate marker for effective treatment in
hormone receptor-positive pre-menopausal breast cancer pa-
tients [4]. This finding suggests that irrespective of chemo-
therapy or endocrine therapy, amenorrhea is important for
pre-menopausal patients who have an ER-positive, HER2-
negative tumour. The trial assigning individualized options
for treatment (TAILORx) and the EORTC 10041/BIG 03-04
(MINDACT) studies can identify patients with a low-risk
profile, thereby justifying the omission of chemotherapy
based on its potentially low benefit [5–8].
Treatment decisions based on demographic characteristics
and tumour burden have the potential to overtreat many in-
dividuals and undertreat others. The Oncotype DX assay has
been studied for lymph node-positive breast cancer patients,
and the SWOG 8818 study reported that the low-risk Onco-
type DX group gained no additional benefits from chemo-
therapy [9]. SOFT and TEXT joint analysis showed excellent
survival data that included lymph node-positive, ER-positive
breast cancer patients who received endocrine therapy alone.
These findings suggested that not all lymph node-positive,
ER-positive, and HER2-negative tumours require chemother-
apy. Apart from the tumour burden, identifying robust bio-
logical predictors of benefit is likely to be informative and
useful. It has been shown that endocrine therapy, which can
substitute for chemotherapy even though there is a high
tumour burden in hormone-responsive breast cancer, is ef-
fective. The factors that determine chemotherapy sensitivity
remain poorly understood and might not entirely overlap
with negative predictors of endocrine sensitivity or prognos-
tic determinants [10, 11].
Neoadjuvant treatment has benefits, which include re-
ducing the tumour burden and evaluating the treatment
response of the tumour. The response to neoadjuvant
chemotherapy (NCT) is diverse and varies according to
the intrinsic subtype. ER-positive, HER2-negative breast
cancer shows a reduced pathologically complete re-
sponse (pCR) rate, but better survival than other sub-
types. Moreover, pCR is not related to survival in the
luminal A subtype [12]. Therefore, the goal of neoadju-
vant treatment for hormone-responsive tumours is to
evaluate the treatment effects and reduce the tumour
size prior to treatment, although it can rarely achieve
pCR. Neoadjuvant endocrine therapy (NET) has been
mostly studied for post-menopausal breast cancer pa-
tients in comparison with tamoxifen and aromatase in-
hibitors [13–15]. Semiglazov et al. compared NET and
chemotherapy for post-menopausal breast cancer pa-
tients and found a similar clinical response between the
two therapies [16]. The STAGE study was conducted for
pre-menopausal breast cancer patients and compared
gonadotropin-releasing hormone agonist (GnRHa) with
tamoxifen and GnRHa with an aromatase inhibitor [17].
However, no clinical trial has yet compared NCT with
NET for pre-menopausal patients.
Therefore, we hypothesised the non-inferior response
of NET compared with NCT and reported a phase III
clinical trial to compare the response between NCT and
NET in pre-menopausal women with ER-positive,
HER2-negative, and lymph node-positive breast cancer.
Methods/design
Study design
This is a phase III, open-label, prospective, randomised,
multicentre, neoadjuvant study of chemotherapy versus
endocrine therapy in pre-menopausal patient with
hormone-responsive, HER2-negative, lymph node-
positive breast cancer [NEST]. Seven centres belonging
to the Korean Breast Cancer Society Group (KBCSG-
012) participated in this study. The study protocol has
been approved by the Korea Food and Drug Administra-
tion (KFDA), as well as the institutional review board of
every trial centre, and was conducted in accordance with
the Declaration of Helsinki, Good Clinical Practice, and
the applicable local regulatory requirements on bioeth-
ics. For safety issue, the response rate of both groups
was planned to be monitored. An independent data
monitoring committee (IDMC) was established to moni-
tor the study progress. The IDMC was responsible for
deciding whether to continue the study when 66 patients
in each treatment group completed their treatment
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regimens. This trial has been registered in ClinicalTrials.
gov as number NCT01622361.
Patients
Eligible patients included pre-menopausal women with
histologically confirmed ER-positive, HER2-negative, and
lymph node-positive primary breast cancer. Lymph node
positivity was required to be proven histologically prior
to the start of treatment with core needle biopsy or fine
needle aspiration. All patients were aged between 20 and
50 years. Pre-menopausal status was defined based on
the following: (1) last menses within 6 months of ran-
domisation and (2) for patients who have had hysterec-
tomy, E2 ≥ 20 pg/ml and FSH < 30 mIU/ml within 4
weeks of randomisation. ER positivity was defined as
Allred score ≥ 3 or modified Allred score ≥ 4. Patients
with inflammatory breast cancer, bilateral breast cancer,
evidence of distant metastasis, or other malignancy were
excluded. Written informed consent was obtained from
all participants.
Randomisation
Patients were enrolled by the study investigators. Pa-
tients were randomly assigned (1:1) to receive either
NCT or NET for 24 weeks prior to surgery. Block ran-
domisation was performed using the e-CRF system, with
patients stratified by the treating centre and clinical
stage (stages II and III). Patients who signed an informed
consent form entered screening and were assigned a
unique patient screening number. Patients who com-
pleted the screening process and met all eligibility cri-
teria were randomised through a central randomisation
website. No patients were enrolled or began treatment
prior to randomisation, and the assignment of a ran-
domisation number was undertaken using the website.
Adverse events were recorded at every patient visit and
assessed according to the Common Terminology Cri-
teria for Adverse Events Version 3.0.
Procedures
Patients were randomly assigned (1:1) to receive either
adriamycin and cyclophosphamide (60 mg/m2 adriamy-
cin plus 600 mg/m2 cyclophosphamide intravenously)
every 3 weeks for 4 cycles, followed by taxol (75 mg/m2
docetaxel intravenously) every 3 weeks for 4 cycles, or
goserelin acetate 3.6 mg every 4 weeks with tamoxifen
20mg daily. Treatment continued for 24 weeks before
surgery (Additional file 1).
All patients underwent breast magnetic resonance im-
aging (MRI) before the start of treatment and after the
end of treatment before surgery. Additionally, during
treatments (every 3 weeks for the NCT group, and every
4 weeks for the NET group), calliper measurement of
the tumour size was performed. We determined the
objective tumour response with every measurement
method and assessed the response according to the
modified RECIST [14]. Surgery was performed between
the 24th and 26th week.
All immunohistochemical analyses of ER and Ki-67 ex-
pression were performed and reviewed at the central la-
boratory (Asan Medical Center, Seoul, South Korea). Ki-67
was stained with an antibody for MIB-1 for assessment,
using a sample of the core biopsy prior to treatment and a
surgery specimen after treatment. The Ki-67 index was cal-
culated as the percentage ratio of Ki-67-positive cells to
total cells.
Outcomes
The primary endpoint was the clinical response rate at
24 weeks, as determined using calliper and MRI mea-
surements. We performed tumour measurements using
callipers every 3 weeks for the NEC group and every 4
weeks for the NCT group, and MRI at day 0 and week
24. A clinical response included either a complete re-
sponse (CR) or a partial response (PR) according to the
Response Evaluation Criteria In Solid Tumour (RECIST)
version 1.1 criteria. Secondary endpoints were the rate
of pCR, the rate of breast conservation surgery, Ki-67
changes, the length of time to maximum response within
a treatment period, and QoL, using the European Or-
ganisation for Research and Treatment of Cancer Qual-
ity of Life (EORTC QOL BR23) questionnaire. Adverse
events were recorded at every patient visit and assessed
according to the Common Terminology Criteria for Ad-
verse Events Version 3.0.
Statistical analysis
The sample size was calculated based on the clinical re-
sponse rate measured by MRI in each group, the NCT
and NET groups, under the assumption that the effect of
NET would be non-inferior to that of NCT. Sample sizes
of 131 in each group achieve 80.055% power to detect a
non-inferiority margin difference between the group
proportions of − 0.1500 (i.e. the lower limit of the two-
sided 95% confidence interval (CI) for the difference in
response rates between groups being 15% or less), when
the MRI response rate of NCT and NET was estimated
to be approximately 75%. A total of 290 patients were
required (145 per treatment group, allowing for a drop-
out rate of 10% in each group).
Because of enrolment failure, a total of 194 patients
were enrolled until September 24, 2014. All data analysis
was performed according to a pre-established analysis
plan. A two-sided 95% confidence interval for the differ-
ence in the incidence of morbidity was calculated to test
for non-inferiority. As a non-inferiority design had been
adopted, difference of the response rate between group
and the 95% CI was calculated, using the index of NCT
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as the reference. NET would be considered to be non-
inferior to NCT when the lower limit of the CI is greater
than − 0.15. Because of enrolment failure, a total of 194
patients were enrolled until September 24, 2014. To
draw a comparison between the two groups, t test for
mean differences and chi-squared test for frequencies
were used. A 2-sided p < 0.05 was considered statistically
significant. All analyses were conducted using SAS ver-
sion 9.4 (SAS Institute; Cary, NC) and R version 3.6.1.
Role of the funding source
AstraZeneca participated in the funding of the study.
The authors had complete access to the study data, and
the corresponding author had the final responsibility for
publication submission.
Results
A total of 187 patients from 7 participating centres were
included and randomised. Seven patients in the NCT
group and 5 patients in the NET group withdraw their
consent. One patient in the NCT group was randomised
but did not receive treatment. Therefore, a total 174 pa-
tients completed the scheduled treatment and were fi-
nally analysed (87 patients received NCT and 87 patients
received NET; Fig. 1). Four patients in the NET group
did not receive the surgery, of whom 3 patients showed
PR and 1 patient showed stable disease (SD). The data
of these 4 patients were excluded from the post-surgery
data (pCR and rate of BCS) analysis (Fig. 1). Baseline
characteristics were generally balanced between the
treatment groups (Table 1). The median age was 42
years (range, 27–54). All patients were pre-menopausal,
and 63% of patients had a normal body mass index.
Sixty-nine percent of patients had a clinical T2 breast
cancer, and 88.5% had a clinical N1 stage breast cancer.
Ninety-four percent of patients had G1/2 breast cancer,
and few patients (less than 5%) had poorly differentiated
(G3) tumour. The mean Ki-67 expression was not differ-
ent between the two groups (26.3 for NCT vs. 26.7 for
NET, p = 0.891). Forty-eight percent of NCT patients
and 61% of NET patients were expected to undergo
mastectomy prior to the start of treatment (p = 0.142).
Tumour size decreased over 24 weeks in both treat-
ment groups (p > 0.05). The clinical response rate mea-
sured using MRI was 83.7% (72 of 87 patients) with
NCT and 52.9% (45 of 87 patients) with NET (estimated
difference 30.8%, 95% CI 17.6–44.0, p < 0.001). On calli-
pers, the clinical response rate was 83.9% (73 of 87
Fig. 1 Trial profile
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patients) with NCT and 71.3% (62 of 87 patients) with
NET (estimated difference 12.6%, 95% CI 0.4–24.9, p =
0.046) (Table 2).
The conversion rate of breast-conserving surgery
(BCS) with neoadjuvant treatment in patients who
planned to have total mastectomy was 13.8% in the NCT
group and 11.5% in the NET group, which was not sig-
nificantly different (p = 0.531). Three NCT patients
(3.4%) and one NET patient (1.2%) showed pCR
(ypT0ypN0M0) (p < 0.005). Twelve NCT patients
(13.8%) and 4 NET patients (4.9%) had complete lymph
node response (p < 0.005). However, Ki-67 expression
change during the treatment period was not significantly
different between the two groups (p = 0.114; − 13.56 for
NCT and − 7.49 for NET).
Nineteen NCT patients (21.8%) had treatment-related
grade 3 or worse adverse events, with no adverse effects
in the NET group.
Exploratory subgroup analysis was performed. There
was a difference of tumour response according to Ki-67
expression. For patients with a low Ki-67 expression (≤
20%), the clinical response rate was 83.7% (41/49) in
NCT, 60.4% (29/48) in NET with MRI, and 69.4% (34/
49) in NCT, 83.3% (40/48) in NET with calliper. Among
the high Ki-67 expression group (> 20%), the response
rate was 81.1% (29/36) in NCT, 40.5% (15/37) in NET
Table 1 Patient demographics and baseline tumour characteristics
Chemotherapy group (n = 87) Endocrine therapy group (n = 87) p value
Age group at baseline(years)
Mean (SD) 42.5 ± 5.6 41.5 ± 5.8 0.255
20–29 2 (2.3%) 2 (2.3%)
30–39 20 (23.0%) 31 (35.6%)
40–49 59 (69.0%) 50 (59.8%)
50–55 6 (5.7%) 4 (2.3%)
BMI (kg/m2) 0.921
< 18.5 5 (5.7%) 4 (4.6%)
18.5–24.9 54 (62.1%) 56 (64.4%)
25–29.9 24 (27.6%) 20 (23.0%)
≥ 30 4 (4.6%) 7 (8.0%)
Clinical T stage 0.746
T1 13 (14.9%) 9 (10.3%)
T2 58 (66.7%) 62 (71.3%)
T3 16 (18.4%) 16 (18.4%)
Clinical N stage 0.808
N1 78 (89.7%) 76 (87.4%)
N2 5 (5.7%) 5 (5.7%)
N3 4 (4.6%) 6 (6.9%)
Grade 0.616
G1/2 52 (59.8%) 61 (70.1%)
G3 3 (3.4%) 4 (4.6%)
NA 32 (36.8%) 22 (25.3%)
Ki-67 expression (%) 0.891
≤ 20% 49 (56.3%) 48 (55.2%)
> 20% 36 (41.4%) 37 (42.6%)
Unknown 2 (2.3%) 2 (2.3%)
Planned operation 0.141
Mastectomy 45 (51.7%) 53 (60.6%)
Breast-conserving surgery 42 (48.3%) 34 (39.1%)
Data are n (%), unless otherwise stated
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by MRI, and 77.8% (28 /36) in NCT, 78.4% (29/37) in
NET by calliper (Table 3, Fig. 2).
Discussion
During 24 weeks of neoadjuvant treatment, in pre-
menopausal, hormone receptor-positive, HER2-negative,
and lymph node-positive breast cancer patients, NCT
achieved a significantly better clinical response rate than
NET. The difference in response was even higher in pa-
tients with a highly proliferating tumour (Ki-67 expres-
sion > 20). Neoadjuvant therapy was comparatively more
effective in patients with low Ki67 (low, 60.4%, vs. high,
40.5%, by MRI) while chemotherapy was equally
effective irrespectively of Ki67 (low, 81.1%, vs. high,
83.7%, by MRI).
This study is the first to compare NCT with NET
(tamoxifen plus ovarian function suppression) in pre-
menopausal breast cancer only. This study is also unique
because the patients were all ER-positive/HER2-negative
and lymph node-positive.
The primary finding of this study was that the re-
sponse to NET was inferior to NCT in pre-menopausal
ER-positive/HER2-negative subtype breast cancer. The
pCR rate was also higher in the NCT group than in the
NET group. However, this does not imply that NCT pa-
tients will have a better long-term survival outcome than
NET patients. First, the changes in Ki-67 expression
Table 2 Summary of clinical response from baseline to week 24
Clinical response Intention to treat population
Chemotherapy group (n = 87) Endocrine therapy group (n = 87)
MRI+
CR 14 (16.3%) 2 (2.3%)
PR 58 (67.4%) 43 (50.6%)
CR + PR 72 (83.7) 45 (52.9%)
Calliper*
CR 27 (31%) 17 (19.5%)
PR 46 (52.9%) 45 (51.5%)
CR + PR 73 (83.9%) 62 (71.3%)
Pathologic response Chemotherapy group (n = 87) Endocrine therapy group (n = 83)
pCR 3 (3.4%) 1 (1.2%)
pCR (breast) 5 (5.7%) 1 (1.2%)
pCR (axillary lymph node) 12 (13.8%) 4 (4.9%)
Data are n (%). CR complete response, PR partial response
+Estimated difference 30.8%, 95% CI 17.6–44.0, p < 0.001
*Estimated difference 12.6%, 95% CI 0.4–24.9, p = 0.046
Table 3 Summary of clinical response from baseline to week 24












arm (n = 37)
Best overall tumour response
MRI
CR 14 (16.3%) 2 (2.3%) 6 (12.2%) 1 (2.1%) 7 (19.4%) 1 (2.7%)
PR 58 (67.4%) 43 (50.6%) 35 (71.4%) 28 (58.3%) 22 (61.1%) 14 (37.8%)
CR +
PR
72 (83.7) 45 (52.9%) 41 (83.7%) 29 (60.4%) 29 (81.1%) 15 (40.5%)
Calliper
CR 27 (31%) 17 (19.5%) 12 (24.5%) 10 (20.8%) 8 (22.2%) 13 (35.5%)
PR 46 (52.9%) 45 (51.5%) 22 (44.9%) 30 (62.5%) 20 (55.6%) 16 (43.2%)
CR +
PR
73 (83.9%) 62 (71.3%) 34 (69.4%) 40 (83.3%) 28 (77.8%) 29 (78.4%)
Data are n (%). CR complete response, PR partial response
Low Ki subgroup: Ki67expression ≤ 20%. High Ki subgroup: Ki67 expression > 20%
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were not different between the two groups. In addition,
NET patients could receive adjuvant chemotherapy in
most cases especially when the response was poor (data
not shown). Long-term follow-up of the two patient
groups is warranted.
Considering pCR and/or clinical response is not a reliable
surrogate endpoint for survival, and the most important
role of neoadjuvant systemic therapy in ER-positive/HER2-
negative breast cancer is expanding the pool of potential
BCS candidates by downstaging tumours and permitting
BCS in patients who would otherwise require mastectomy
[18]. In our study, although NCT led to a better clinical re-
sponse, the BCS rate was not different between the two
groups. Therefore, for the purpose of enabling BCS for
mastectomy candidates, NCT might not be a better option
than NET.
A potential advantage of neoadjuvant therapy is avoid-
ance of axillary lymph node dissection in patients who
have had negative conversion of tumour-positive lymph
nodes. NCT downstages axillary nodes in 20 to 40% of pa-
tients, and these rates are even higher (> 50%) in HER2-
positive patients given anti-HER2 therapy [19–21]. Two
recent prospective trials (ACOSOG Z1071 and SENTINA)
reported that the false-negative rate was reasonably low
when a dual tracer was used and 3 or more sentinel nodes
were harvested [22, 23]. Kang et al. showed that in breast
cancer patients who had axillary lymph node conversion
from clinically positive to negative following NCT, a senti-
nel lymph node biopsy-guided axillary operation had simi-
lar rates of axillary and distant recurrence with axillary
lymph node dissection without sentinel node biopsy [24].
Our study showed that for the purpose of avoiding lymph
node dissection, NCT can be better than NET because the
CR in lymph nodes was significantly higher in the NCT
group than in the NET group (13.8% vs. 4.6%). However,
further study is needed as to whether complete axillary
lymph node dissection has survival benefit and should be
a mandatory procedure for patients who have metastasis
in a limited number of axillary lymph nodes after NCT or
NET.
Most NET studies in breast cancer have focused on
post-menopausal women [12, 13, 25, 26]. Few data are
available on NET in pre-menopausal women. Some
studies have shown that NET could be effective in well-
selected pre-menopausal patients [17, 27]. GEICAM has
reported randomised phase II results of chemotherapy
versus exemestane in pre- and post-menopausal women
[28]. Although the sample size was small, the response
rate was higher for chemotherapy than for endocrine
therapy in pre-menopausal patients, which was consist-
ent with our study. The two therapies were comparable
in post-menopausal women and those with a low base-
line Ki-67.
The optimal duration of NET is not well defined. Most
previous NET studies applied from 3 to 6 months of
therapy. In a study by Llombart-Cussac et al. [26], 37%
of patients achieved the maximal response beyond 6
months. Carpenter et al. showed that median time to
achieve BCS (in those who responded) was 7.5 months
[29]. Notably, 62% of panellists at St Gallen 2013 were in
favour of continuing NET until a maximal response [30].
In our study, the patients received 6 months of NET. If
we had treated to the maximal response for these pa-
tients, the response might have been better.
For ER-positive/HER2-negative subtype breast cancer,
objective response determination is an issue. pCR, which
is the only definite response criteria in neoadjuvant ther-
apy, is highly uncommon; furthermore, it is not a surro-
gate endpoint for survival in this subtype [31]. We
evaluated the clinical response using MRI and callipers.
Even though MRI is a useful method for measuring re-
sidual tumour size after neoadjuvant treatment, it is not
well correlated with pathologic size in ER-positive,
HER2-negative tumours [32]. In our study, there was
also a large discrepancy between MRI size and patho-
logic tumour size in the NCT group (data not shown).
The difference in response pattern in the tumour be-
tween endocrine therapy and chemotherapy makes an
objective response determination and comparison diffi-
cult and somewhat imbalanced.
There are some limitations in this study. First, the
small sample size which was not satisfied with pre-
defined number was included. Second, clinical response
or pCR is not a predictor of prognosis in ER-positive
Fig. 2 Response rate according to treatments. a Clinical response measure by calliper. b Clinical response measure by MRI. c Detailed clinical
response measure by calliper. d Detailed clinical response measure by MRI
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and Her2-negative subtypes. This data cannot demon-
strate the survival benefit of NCT compared with NET.
Third, we did not include the arm of aromatase inhibitor
as a NET treatment. In a study that compared neoadju-
vant GnRH analogue plus tamoxifen and GnRH
analogue plus anastrozole in pre-menopausal women,
the clinical response was better in the anastrozole group
[17]. Because we did not consider an aromatase inhibi-
tor, a question remains concerning the response com-
parison between chemotherapy versus ovarian function
suppression with aromatase inhibitor in pre-menopausal
women. Lastly, multigene assays were not evaluated.
Although, in our result for the primary endpoint, NET
showed a worse clinical response than NCT, NET can-
not be excluded as a clinical option, because (1) the BCS
rate was comparable, (2) no difference was observed in
Ki-67 change with the therapies, and (3) the adverse
event was much smaller in the NET group. This finding
indicates that we can recommend NET in clinical prac-
tice in ER-positive/HER2-negative breast cancer with
low Ki-67 expression, intermediate/low grade tumour,
clinically lymph node-negative patients, and for patients
with large tumours where BCS is not feasible or equivo-
cal. It is recommended to perform a multigene assay
(e.g. Oncotype DX, Mammprint) prior to the start of
NET to confirm whether chemotherapy is needed for
the individual patient.
Conclusion
In pre-menopausal breast cancer patients, 24 weeks of
NCT showed a better clinical response than NET except
for in a subgroup with low Ki-67 or low grade cancer.
However, the breast conservation rate and the Ki-67
change were not different. There may be an issue con-
cerning accurate size measurements with MRI in both
groups. Clinicians should be aware of the potential bene-
fits and disadvantages of both treatments. Use of NET in
pre-menopausal women requires further discussion.
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